抗精神病药未治疗的首发精神病患者海马亚区体积与海马谷氨酸水平的纵向研究
研究纳入93例未用药首发精神病患者和80名匹配健康对照,在基线及抗精神病药治疗6周和16周时测量左侧海马亚区体积与谷氨酸水平。患者基线CA1和前下托体积减低,至16周扩展至齿状回分子与颗粒细胞层及CA4;基线谷氨酸与对照无显著差异,治疗无影响,且与体积或体积变化无关。
要点
- 首发精神病患者基线CA1和前下托体积减低,16周时扩展至齿状回分子与颗粒细胞层及CA4。
- 患者基线海马谷氨酸水平与健康对照无显著差异,抗精神病药治疗对谷氨酸无显著影响。
- 谷氨酸水平与基线亚区体积及16周内体积变化均无关。
核心结论
- 首发精神病患者开始治疗后16周内海马亚区体积进行性减低,提示神经病理早期进展。
- 结果不支持谷氨酸作为驱动因素。
- 作者认为需进一步研究该现象的机制,因其对早期干预以保护首发精神病患者认知减退有启示。
研究设计与样本
- 纵向研究纳入93例未用药首发精神病患者和80名匹配健康对照。
- 在基线及抗精神病药治疗6周和16周时采集T1、T2加权图像及左侧海马体素磁共振波谱数据。
- 海马亚区体积用FreeSurfer 7.1.1评估,谷氨酸水平用jMRUI 6.0量化,数据分析采用线性混合模型。
主要发现
- 首发精神病患者基线CA1和前下托存在区域性亚区体积减低。
- 至第16周体积减低扩展至齿状回分子与颗粒细胞层(GC/ML/DG)及CA4。
- 首发精神病患者基线海马谷氨酸水平与健康对照无显著差异,治疗对谷氨酸无显著影响。
- 谷氨酸水平与初始亚区体积及16周内体积变化均无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have implicated hippocampal abnormalities in the neuropathology of psychosis spectrum disorders. Reduced hippocampal volume has been reported across all illness stages, and this atrophy has been hypothesized to be the result of glutamatergic excess. To test this hypothesis, we measured hippocampal subfield volumes and hippocampal glutamate levels in antipsychotic naïve first episode psychosis patients (FEP) and the progression of volume decline and changes in glutamate levels over a 16-week antipsychotic drug (APD) trial. We aimed to determine if subfield volumes at baseline were associated with glutamate levels, and if baseline glutamate levels were predictive of change in subfield volumes over time. METHODS: We enrolled ninety-three medication-naïve FEP participants and 80 matched healthy controls (HC). T1 and T2 weighted images and magnetic resonance spectroscopy (MRS) data from a voxel prescribed in the left hippocampus were collected from participants at baseline and after 6 and 16 weeks of APD treatment. Hippocampal subfield volumes were assessed using FreeSurfer 7.1.1., while glutamate levels were quantified using jMRUI version 6.0. Data were analyzed using linear mixed models. RESULTS: We found regional subfield volume deficits in the CA1, and presubiculum in FEP at baseline, that further expanded to include the molecular and granule cell layer of the dentate gyrus (GC/ML/DG) and CA4 by week 16. Baseline hippocampal glutamate levels in FEP were not significantly different than those of HC, and there was no effect of treatment on glutamate. Glutamate levels were not related to initial subfield volumes or volume changes over 16 weeks. CONCLUSION: We report a progressive loss of hippocampal subfield volumes over a period of 16 weeks after initiation of treatment, suggestive of early progression in neuropathology. Our results do not suggest a role for glutamate as a driving factor. This study underscores the need to further research the mechanism(s) underlying this phenomenon as it has implications for early intervention to preserve cognitive decline in FEP participants.
引用
- Nelson EA, Kraguljac NV, Bashir A, et al. A longitudinal study of hippocampal subfield volumes and hippocampal glutamate levels in antipsychotic-naïve first episode psychosis patients. Mol Psychiatry. 2024. PMID: 39580605. doi:10.1038/s41380-024-02812-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。